Subscribe

Spotlight -

Eduardo Mysler, MD

Eduardo Mysler, MD

Executive medical director, Organización Medica de Investigación, Argentina

Articles by Eduardo Mysler, MD

Switch, Don’t Cycle: Upadacitinib Outperforms Adalimumab in RA Post-TNFi, With Eduardo Mysler, MD

Switch, Don’t Cycle: Upadacitinib Outperforms Adalimumab in RA Post-TNFi, With Eduardo Mysler, MD

ByEduardo Mysler, MD

October 23rd 2025

Mysler emphasized the first definitive evidence informing sequencing after failing a first TNF inhibitor.

Latest Updated Articles

Switch, Don’t Cycle: Upadacitinib Outperforms Adalimumab in RA Post-TNFi, With Eduardo Mysler, MD
October 23rd 2025

Trending on Rheumatology Live

Bimekizumab Beats Risankizumab on ACR50 in First IL-17A/F vs IL-23 Head-to-Head

TOGETHER-PsA:Tirzepatide + Ixekizumab Rapidly Improves PsA Disease Control With Obesity/Overweight

Early Joint Clearance With Bimekizumab Leads to Durable Disease Control in PsA

Autoantibody and IFN Burden Correlate With Nipocalimab Response in Sjögren's Disease

OLINGUITO: Filgotinib Meets Phase 3 Primary Endpoint in r/nr-axSpA, With Xenofon Baraliakos, MD, PhD